Regulation of p53 downstream genes - PubMed

Review

Regulation of p53 downstream genes

W S el-Deiry. Semin Cancer Biol. 1998.

Free article

Abstract

The p53 tumor suppressor is the most commonly mutated gene in human cancer. p53 protein is stabilized in response to different checkpoints activated by DNA damage, hypoxia, viral infection, or oncogene activation resulting in diverse biological effects, such as cell cycle arrest, apoptosis, senescence, differentiation, and antiangiogenesis. The stable p53 protein is activated by phosphorylation, dephosphorylation and acetylation yielding a potent sequence-specific DNA-binding transcription factor. The wide range of p53's biological effects can in part be explained by its activation of expression of a number of target genes including p21WAFI, GADD45, 14-3-3 sigma, bax, Fas/APO1, KILLER/DR5, PIG3, Tsp1, IGF-BP3 and others. This review will focus on the transcriptional targets of p53, their regulation by p53, and their relative importance in carrying out the biological effects of p53.

Similar articles

• [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].

  Mendoza-Rodríguez CA, Cerbón MA. Mendoza-Rodríguez CA, et al. Rev Invest Clin. 2001 May-Jun;53(3):266-73. Rev Invest Clin. 2001. PMID: 11496714 Review. Spanish.

• Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.

  Burns TF, Bernhard EJ, El-Deiry WS. Burns TF, et al. Oncogene. 2001 Aug 2;20(34):4601-12. doi: 10.1038/sj.onc.1204484. Oncogene. 2001. PMID: 11498783

• The role of p53-target genes in human cancer.

  Tokino T, Nakamura Y. Tokino T, et al. Crit Rev Oncol Hematol. 2000 Jan;33(1):1-6. doi: 10.1016/s1040-8428(99)00051-7. Crit Rev Oncol Hematol. 2000. PMID: 10714958 Review.

• Identification of a novel p53 functional domain that is necessary for efficient growth suppression.

  Walker KK, Levine AJ. Walker KK, et al. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15335-40. doi: 10.1073/pnas.93.26.15335. Proc Natl Acad Sci U S A. 1996. PMID: 8986812 Free PMC article.

• Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

  Takimoto R, El-Deiry WS. Takimoto R, et al. Oncogene. 2000 Mar 30;19(14):1735-43. doi: 10.1038/sj.onc.1203489. Oncogene. 2000. PMID: 10777207

Cited by

• Differences in the transactivation domains of p53 family members: a computational study.

  Mavinahalli JN, Madhumalar A, Beuerman RW, Lane DP, Verma C. Mavinahalli JN, et al. BMC Genomics. 2010 Feb 10;11 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2164-11-S1-S5. BMC Genomics. 2010. PMID: 20158876 Free PMC article.

• SAGE Genie: a suite with panoramic view of gene expression.

  Liang P. Liang P. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11547-8. doi: 10.1073/pnas.192436299. Epub 2002 Aug 23. Proc Natl Acad Sci U S A. 2002. PMID: 12195021 Free PMC article. No abstract available.

• Tumor-derived p53 mutants induce NF-kappaB2 gene expression.

  Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, Deb SP, Deb S. Scian MJ, et al. Mol Cell Biol. 2005 Nov;25(22):10097-110. doi: 10.1128/MCB.25.22.10097-10110.2005. Mol Cell Biol. 2005. PMID: 16260623 Free PMC article.

• The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter.

  Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. Zhang W, et al. J Biol Chem. 2000 Jun 16;275(24):18391-8. doi: 10.1074/jbc.C000062200. J Biol Chem. 2000. PMID: 10749849 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal